Upstream Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
460 Totten Pond Rd Ste 420, Waltham, Mas...Website
www.upstreambio.comRevenue
<$5 MillionStock Symbol
UPBIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Upstream Bio
At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases.Explore more
Upstream Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Upstream Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Upstream Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Upstream Bio
Product Launch: Get notified when Upstream Bio launches new products
Earning: See what the market has to say on Upstream Bio recently announced quarterly report
Funding: Get notified immidiatlly once Upstream Bio has new funding data
Website visits: Recent activity has been detected on your website
Check out if Upstream Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Upstream Bio had a recent Job posting/layoffs
Check if Upstream Bio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Upstream Bio as Masked Content
Find 2 more new buyers
Compare Similar Companies to Upstream Bio
Compare insights from companies similar to Upstream Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Upstream Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Upstream Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Upstream Bio.
Upstream Bio financials insights
Gather financial insights about Upstream Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$2B
2023
Series B
$200M
2024
Stock Offering
$255M
Upstream Bio Tech Stack
A closer look at the technologies used by Upstream Bio
Most Recent Scoops
Person-Based
Michael Gray sold 853 shares for $5,203.30 in June 2026, contributing to negative insider sentiment.
Stake & Stock Ownership, Finance, Financial Transactions
Person-Based
Pharmaceuticals, Clinical Operations
Facilities Relocation / Expansion
Upstream Bio is planning to move offices in January 2027. The move will impact approximately 50 employees at the existing office located at 890 Winter Street, Waltham, MA.
Facilities Relocation/Expansion
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Upstream Bio News & Media
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track –Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –Upstream Bio, Inc. (UPB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Upstream Bio, Inc. (UPB) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:40 AM EDTCompany ParticipantsE.Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026
WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that additional data from its Phase 2 VIBRANT trial of verekitug in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) will be presented in an oral session at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Congress in Istanbul, Turkey,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Upstream Bio
Sign Up For FreeTo access detailed company insights
At Upstream Bio we strive to reach the source of inflammation and conquer it. Our lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases.... Read More
